Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Lab Med. 2014 Jun;34(2):337-49. doi: 10.1016/j.cll.2014.02.007. Epub 2014 Apr 12.

Interferon-gamma release assays.

Author information

1
Denver Public Health Department, University of Colorado School of Medicine, 605 Bannock Street, Denver, CO 80204, USA. Electronic address: robert.belknap@dhha.org.
2
National Jewish Health, University of Colorado School of Medicine, 1400 Jackson Street, Denver, CO 80206, USA.

Abstract

Diagnosis of latent tuberculosis infection (LTBI) should be targeted toward individuals and groups with high risk of progression to active tuberculosis (TB). Low-risk populations should not be screened. Interferon-gamma release assays (IGRAs) perform as well or better than the tuberculin skin test in most targeted populations. IGRAs are preferred for bacille Calmette-Guérin (BCG)-vaccinated populations. A positive IGRA in a person at low risk for TB exposure should be confirmed with a repeat test or another method before recommending LTBI treatment. The choice of which IGRA to use is generally based on the costs and feasibility of performing the test.

KEYWORDS:

Interferon-gamma release assays; Latent tuberculosis infection; QuantiFERON; T-SPOT; Tuberculin skin test; Tuberculosis

PMID:
24856531
DOI:
10.1016/j.cll.2014.02.007
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center